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Editors: Anton N. Sidawy and Bruce A. PerlerSafety and effectiveness of the INCRAFT AAA Stent Graft
for endovascular repair of abdominal aortic aneurysms
Giovanni Torsello, MD, Dierk Scheinert, MD, PhD, Jan S.
Brunkwall, MD, PhD, Roberto Chiesa, MD, Gioachino Coppi,
MD, Carlo Pratesi, MD
Objective: This study evaluated the 2-year safety and
effectiveness of the European First-in-Human INNOVATION
trial for the INCRAFT AAA Stent Graft system (Cordis Corp,
Bridgewater, NJ), an ultra-low-proﬁle device for the treat-
ment of abdominal aortic aneurysms.
Methods: From March 2010 to June 2011, the INNOVATION
prospective multicenter trial involving six centers in Europe
enrolled and treated 60 asymptomatic patients (95% male;
mean age, 74.4 6.9 years) with the INCRAFT System. Main
inclusion criteria included proximal aortic neck length of
15 mm or more with a diameter up to 27 mm; distal iliac
landing zones with a length greater than 10 mm and a
diameter between 9 and 18 mm; and aortic bifurcation
>18 mm in diameter and access vessels large enough to
accept the 14F outer diameter of the delivery system. The
primary end point was technical success at 1 month; 2-year
safety end points included the absence of device- or pro-
cedure-related major adverse events, absence of type I or III
endoleaks, and maintenance of device integrity through
2 years of follow-up. Study oversight was provided by a
Data Safety Monitoring Board with event adjudication by a
Clinical Events Committee and imaging analysis by an
independent core laboratory.
Results: Of 60 successfully treated patients, two did not
come back for their 1-month evaluation but remained
enrolled in the study; 56 were evaluated at 1 year and 52 at
2 years. Of the 58 patients, 56 met the 1-month primary
safety and effectiveness end point (97%; 95% conﬁdence
interval, 88%-100%). All patients were free from aneurysm
enlargement through 2 years. There were no type I or III
endoleaks at the 2-year time point. All-cause mortality at
2 years was 11.5%, and no death was device or procedure
related. In total, three patients required a postprocedure
intervention, two to repair a type I endoleak and one for
limb occlusion. Core laboratory evaluation of the post-
operative imaging studies documented absence of endog-
raft migration and stent fractures in all patients.
Conclusions: The INCRAFT AAA Stent Graft System provides
a durable solution for patients with abdominal aortic*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(14)00679-0aneurysms, with a low frequency of device-related events
through 2 years of follow-up.Standard endovascular treatment of abdominal aortic
aneurysms in patients with very short proximal necks
using the Endurant stent graft
Miltiadis Matsagkas, MD, PhD, FEBVS, George Kouvelos,
MD, PhD, Michalis Peroulis, MD, PhD, Stavros Avgos, MD,
Eleni Arnaoutoglou, MD, PhD, Nektario Papa, MD, George
Papadopoulos, MD, PhD
Objective: This study evaluated and compared the midterm
results of endovascular aortic aneurysm repair with the
Endurant (Medtronic Inc, Santa Rosa, Calif) stent graft sys-
tem in off-label use in patients with short (<10 mm)
proximal aortic necks and in patients treated according to
device-speciﬁc instructions for use.
Methods: This was a case-control (2:1) single-center ret-
rospective analysis of prospectively collected data per-
formed between September 2008 and December 2012.
Analysis identiﬁed 19 elective patients with short (<10 mm)
proximal necks and mild angulations (45) treated with
the Endurant stent graft and 38 patients matched for age,
sex, and aneurysm diameter with proximal aortic necks
âU10 mm in length who met the instructions for use. End
points included technical and clinical success and freedom
from any secondary intervention, any type of endoleak, and
aneurysm-related death.
Results: The short-neck group was a mean  standard
deviation age of 71.7  8.9 years, 84% were men, and
their mean infrarenal aortic neck length was 6.1  1.2 mm.
Mean suprarenal and infrarenal angles were 110  10.4
and 170  15.4, respectively. Aortic neck diameters were
similar between the groups (26.6  3.8 vs 25.7  3.7 mm;
P = .36). Primary technical success was achieved in all
cases. Off-label patients were more likely to require addi-
tional proximal cuff deployment to successfully obtain a
seal (21% vs 3%; P = .04). The two patient groups were
similar in rates of perioperative mortality, morbidity, and
complications. Mean follow-up of 24  12 months
revealed no differences in clinical success, freedom from
reintervention, and aneurysm-related death. No type I
endoleaks were observed in either group during the fol-
low-up period.
Conclusions: The Endurant stent graft system applied off-
label in patients with very short aneurysm necks (<10 mm)
with mild angulation showed acceptable treatment results.
These midterm results might suggest its use in carefully
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data are needed to verify the observed durability of the
Endurant stent graft.:The Abdominal Aortic Aneurysm Statistically Corrected
Operative Risk Evaluation (AAA SCORE) for predicting
mortality after open and endovascular interventions
Graeme K. Ambler, MB BChir, BSc, PhD, MRCS, Manjit S.
Gohel, MD, FRCS, FEBVS, David C. Mitchell, MA, MB BS, MS,
FRCS, Ian M. Loftus, BSc, MB ChB, MD, FRCS, Jonathan R.
Boyle, MB ChB, MD, MA, FRCS
Background: Accurate adjustment of surgical outcome data
for risk is vital in an era of surgeon-level reporting. Current
risk prediction models for abdominal aortic aneurysm (AAA)
repair are suboptimal. We aimed to develop a reliable risk
model for in-hospital mortality after intervention for AAA,
using rigorous contemporary statistical techniques to han-
dle missing data.
Methods: Using data collected during a 15-month period in
the United Kingdom National Vascular Database, we applied
multiple imputation methodology together with stepwise
model selection to generate preoperative and perioperative
models of in-hospital mortality after AAA repair, using two
thirds of the available data. Model performance was then
assessed on the remaining third of the data by receiver
operating characteristic curve analysis and compared with
existing risk prediction models. Model calibration was
assessed by Hosmer-Lemeshow analysis.
Results: A total of 8088 AAA repair operations were
recorded in the National Vascular Database during the study
period, of which 5870 (72.6%) were elective procedures.
Both preoperative and perioperative models showed
excellent discrimination, with areas under the receiver
operating characteristic curve of .89 and .92, respectively.
This was signiﬁcantly better than any of the existing models
(area under the receiver operating characteristic curve for
best comparator model, .84 and .88; P < .001 and P = .001,
respectively). Discrimination remained excellent when only
elective procedures were considered. There was no evi-
dence of miscalibration by Hosmer-Lemeshow analysis.
Conclusions: We have developed accurate models to assess
risk of in-hospital mortality after AAA repair. These models
were carefully developed with rigorous statistical method-
ology and signiﬁcantly outperform existing methods for
both elective cases and overall AAA mortality. These models
will be invaluable for both preoperative patient counseling
and accurate risk adjustment of published outcome data.Clinical outcomes of different approaches to aortic arch
disease
Arudo Hiraoka, MD, Genta Chikazawa, MD, PhD, Kentaro
Tamura, MD, Toshinori Totsugawa, MD, PhD, Taichi Sakaguchi,
MD, PhD, Hidenori Yoshitaka, MD, PhDObjective: The aim of this study was to evaluate the mid-
term clinical outcomes of various approaches, including
hybrid procedures, to aortic arch pathologies.
Methods: Of 305 consecutive patients who underwent
aortic arch repair between 2005 and 2013, 244 underwent
conventional open total aortic arch repair (CTAR) with
antegrade cerebral perfusion under circulatory arrest, 35
underwent debranching of the arch with thoracic endo-
vascular aortic repair (DTEVAR), and 26 underwent staged
TEVAR after TAR with elephant trunk (TARET). We retro-
spectively evaluated the outcomes of the three groups.
Results: The DTEVAR group had a greater percentage of
patients with preoperative comorbidities. Signiﬁcant dif-
ferences were observed in 30-day mortality (DTEVAR, 14.3%
[5 of 35] vs TARET TEVAR, 0% [0 of 26] vs CTAR, 5.3% [13 of
244]; P = .045) and stroke (DTEVAR, 28.6% [10 of 35] vs
TARET TEVAR, 7.7% [2 of 26] vs CTAR, 8.2% [20 of 244]; P =
.001). In overall midterm survival, the DTEVAR group had a
lower survival rate (63.9% 3-year survival) compared with
the CTAR (90.1% 7-year survival) and the TARET TEVAR
(95.5% 2.5-year survival) groups. In elective cases, better
midterm results were observed in CTAR and TARET TEVAR
groups. An increased number of debranching graft and
emergency operations resulted in a much lower follow-up
survival rate in the DTEVAR group. Atherosclerotic disease
had a great effect on midterm outcomes in the DTEVAR (P =
.045) and CTAR groups (P = .002).
Conclusions: The clinical feasibility of DTEVAR for high-risk
patients requiring zone 0 landing or emergency surgery is
still controversial. Atherosclerotic disease of the aorta has a
signiﬁcant negative effect on midterm outcomes in any
surgical approach.The impact of intraoperative shunting on early neurologic
outcomes after carotid endarterectomy
Kyla M. Bennett, MD, John E. Scarborough, MD, Mitchell W.
Cox, MD, Cynthia K. Shortell, MD
Background: Although the need for intraoperative shunting
during carotid endarterectomy (CEA) is intensely debated,
relatively few studies have compared the neurologic out-
comes of patients undergoing CEA with or without shunts.
The objective of our analysis was to determine the impact
of intraoperative shunting during CEA on the incidence of
postoperative stroke.
Methods: The 2012 CEA-targeted American College of
Surgeons National Surgical Quality Improvement Program
database was used for this analysis. The preoperative and
operative characteristics of patients undergoing CEA with or
without intraoperative shunting were compared. From this
overall sample, propensity score techniques were then used
to match patients with or without intraoperative shunting
for a number of variables, including age, degree of ipsi-
lateral and contralateral carotid stenosis, presence of sev-
eral anatomic or physiologic risk factors, anesthesia
modality, and use of patch angioplasty vs primary arterio-
tomy closure. The 30-day postoperative mortality and
110 Abstractscombined stroke/transient ischemic attack (TIA) rates of this
matched cohort were then compared. A similar analysis was
also performed on a subgroup of patients with severe
stenosis or occlusion of the contralateral carotid artery.
Results: A total of 3153 patients were included for initial
analysis (2023 â no-shuntâ patients vs 1130 â shuntâ
patients). From this overall sample, propensity score
matching yielded a cohort of 1072 patients with or without
intraoperative shunt placement who were well matched for
all known patient- and procedure-related factors. There was
no signiﬁcant difference in the incidence of postoperative
stroke/TIA between the two groups of this matched cohort
(3.4% in the no-shunt group vs 3.7% in the shunt group; P =
.64). Analysis of a similarly well matched subgroup of
patients with severe stenosis or occlusion of the con-
tralateral carotid artery demonstrated a statistically non-
signiﬁcant increase in the incidence of postoperative stroke/
TIA with the use of intraoperative shunting (4.9% in the no-
shunt group vs 9.8% in the shunt group; P = .08).
Conclusions: There is no clinical beneﬁt to intraoperative
shunting during CEA, even in patients who may be at high
risk for intraoperative cerebral hypoperfusion due to severe
stenosis or occlusion of the contralateral carotid artery.Carotid artery stenting has increased risk of external
carotid artery occlusion compared with carotid
endarterectomy
Kevin Brown, MD, Dina S. Itum, MD, Joshua Preiss, Yazan
Duwayri, MD, Ravi K. Veeraswamy, MD, Atef Salam, MD,
Thomas F. Dodson, MD, Luke P. Brewster, MD
Objective: The external carotid artery (ECA) can be an
important source of cerebral blood ﬂow in cases of high-
grade internal carotid artery stenosis or occlusion. However,
the treatment of the ECA is fundamentally different
between carotid endarterectomy (CEA) and carotid artery
stenting (CAS). CEA is routinely associated with endarter-
ectomy of the ECA, whereas CAS excludes the ECA from
direct ﬂow. We hypothesize that these differences make
ECA occlusion more common after CAS. Further, the impact
of CAS on blood ﬂow into the ECA is interesting because the
ﬂow from the stent into the ECA is altered in a way that
may promote local inﬂammation and may inﬂuence in-stent
restenosis (ISR). Thus, our objective was to use our insti-
tutional database to identify whether CAS increased the
rate of ECA occlusion and, if it did, whether ECA occlusion
was associated with ISR.
Methods: Patients undergoing CAS or CEA from February
2007 to February 2012 were identiﬁed from our institu-
tional carotid therapy database. Preoperative and post-
operative images of patients who followed up in our
institution were included in the analysis of ECA occlusion
and rates of ISR.
Results: There were 210 (67%) CAS patients and 207 (60%)
CEA patients included in this analysis. Despite CAS patients
being younger (68 vs 70 years), having shorter follow-up
(12.5 vs 56.2 months), and being more likely to takeclopidogrel (97% vs 35%), they had an increased rate of ECA
occlusion (3.8%) compared with CEA patients (0.4%). CAS
patients who went on to ECA occlusion had an increased
incidence of prior neck irradiation (50% vs 15%; P = .03), but
we did not identify an association of ECA occlusion with ISR
>50%.
Conclusions: Whereas prior publications have identiﬁed
increased rates of external carotid stenosis, this is the ﬁrst
demonstration of increased ECA occlusion after CAS. How-
ever, ECA occlusion is uncommon (â¼4%) and did not have
an association with ISR >50%. Future work modeling ECA
ﬂow patterns before and after CAS will be used to further
test this interaction.Statin therapy after infrainguinal bypass surgery for critical
limb ischemia is associated with improved 5-year survival
Bjoern D. Suckow, MD, MS, Larry W. Kraiss, MD, Andres
Schanzer, MD, David H. Stone, MD, Jeffrey Kalish, MD,
Randall R. DeMartino, MD, Jack L. Cronenwett, MD, Philip P.
Goodney, MD, MS
Objective: Although statin therapy has been linked to fewer
short-term complications after infrainguinal bypass, its effect
on long-term survival remains unclear. We therefore exam-
ined associations between statin use and long-termmortality,
graft occlusion, and amputation after infrainguinal bypass.
Methods: We used the Vascular Study Group of New Eng-
land registry to study 2067 patients (71% male; mean age,
67  11 years; 67% with critical limb ischemia [CLI]) who
underwent infrainguinal bypass from 2003 to 2011. Of
these, 1537 (74%) were on statins perioperatively and at 1-
year follow-up, and 530 received no statin. We examined
crude, adjusted, and propensity-matched rates of 5-year
surviva1, 1-year amputation, graft occlusion, and perioper-
ative myocardial infarction.
Results: Patients taking statins at the timeof surgery and at the
1-year follow-up were more likely to have coronary disease
(38% vs 22%; P < .001), diabetes (51% vs 36%; P < .001),
hypertension (89% vs 77%; P < .001), and prior revasculariza-
tion procedures (50% vs 38%; P < .001). Despite higher
comorbidity burdens, long-term survivalwas better for patients
taking statins in crude (risk ratio [RR], 0.7; P < .001), adjusted
(hazard ratio, 0.7; P = .001), and propensity-matched analyses
(hazard ratio, 0.7; P = .03). In subgroup analysis, a survival
advantage was evident in patients on statins with CLI (5-year
survival rate, 63% vs 54%; log-rank, P = .01) but not claudication
(5-year survival rate, 84% vs 80%; log-rank, P = .59). Statin
therapy was not associated with 1-year rates of major ampu-
tation (12% vs 11%; P = .84) or graft occlusion (20% vs 18%; P =
.58) in CLI patients. Perioperative myocardial infarction occur-
redmore frequently in patientson a statin in crude analysis (RR,
2.2; P = .01) but not in the matched cohort (RR, 1.9; P = .17).
Conclusions: Statin therapy is associated with a 5-year
survival beneﬁt after infrainguinal bypass in patients with
CLI. However, 1-year limb-related outcomes were not
inﬂuenced by statin use in our large observational cohort of
patients undergoing revascularization in New England.
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limb ischemia with comparison to patients undergoing
high-risk bypass grafts
Kristina A. Giles, MD, Eva M. Rzucidlo, MD, Philip P. Goodney,
MD, MS, Daniel B. Walsh, MD, Richard J. Powell, MD
Objective: Bonemarrow cell therapy (BMCT) for patients with
critical limb ischemia (CLI) is a potential treatment in candi-
dates with poor options for standard revascularization pro-
cedures. Whereas clinical trials are ongoing, there are few
comparative data to assess its efﬁcacy compared with bypass.
Methods: Patients with poor revascularization options
underwent BMCT between 2011 and 2013. Outcomes were
compared with those of a cohort of CLI patients undergoing
infrainguinal bypass thought to be at high risk for graft
failure (tissue loss, a tibial target, and a previous endovas-
cular treatment or bypass). BMCT patients underwent har-
vest of bone marrow that was then concentrated and
injected intramuscularly into the ischemic limb.
Results: There were 20 BMCT patients and 35 high-risk
bypass patients. All BMCT patients had either rest pain(80%) or tissue loss (80%). The majority (65%) had a prior
intervention (bypass, 30%; endovascular, 58%) compared
with high-risk bypass patients, all of whom had previous
revascularization attempts (bypass, 43% [P = .35]; endo-
vascular, 77% [P = .14]). Mean follow-up was 773 days after
BMCT and 972 days after high-risk bypass. All patients
tolerated BMCT without issues or complications. A second
BMCT treatment was performed in 21% because of clinical
deterioration. Wound healing occurred in 75% at 1.5 years,
including patients receiving second injections, all of which
resolved. Rest pain improved in 87.5% of patients. Pain
completely resolved in 58% at 1.5 years. Ankle-brachial
index improvement was 0.23 (0.25). Three BMCT patients
went on to amputation. One-year freedom from major
amputation or death was 78% for BMCT vs 69% for high-risk
bypass (P = .60).
Conclusions: BMCT is a potential option in CLI patients who
are not candidates for bypass or endovascular intervention.
Limb salvage is unexpectedly high in this population with
few other options.
